Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465196 | 1.00 | HTR2A (0.41) | HTR2ATAAR1ALDH1A1MAPTGAA | |
| SCHEMBL3465279 | 0.87 | HTR2A (0.42) | HTR2ATAAR1ALDH1A1MAPTGAA | |
| SCHEMBL3465361 | 0.87 | HTR2A (0.42) | HTR2ATAAR1ALDH1A1MAPTGAA | |
| SCHEMBL13981506 | 0.85 | ACHE (0.47) | ALDH1A1MAPTGAA | |
| SCHEMBL28103261 | 0.85 | ACHE (0.47) | ALDH1A1MAPTGAA | |
| SCHEMBL16649296 | 0.81 | TAS1R3 (0.48) | — | |
| Hydrochloric Acid SCHEMBL3825173 | 0.81 | PPARG (0.44) | HTR2ATAAR1ALDH1A1MAPT | |
| SCHEMBL29572058 | 0.81 | TAS1R3 (0.48) | — | |
| SCHEMBL30385392 | 0.78 | HTR2A (0.46) | HTR2ATAAR1ALDH1A1GAA | |
| SCHEMBL15210443 | 0.78 | HTR2A (0.46) | HTR2ATAAR1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | HTR2A 3250/4885TAAR1 186/4885ALDH1A1 523/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | HTR2A 3700/4885TAAR1 793/4885ALDH1A1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.